Introduction: Follicular non-Hodgkin lymphoma (FNHL), the second most common subtype of non-Hodgkin lymphoma and the seventh most frequent cancer in Western countries, is characterized by the malignant proliferation of germinal center B cells within lymphoid follicles. It predominantly affects supradiaphragmatic and abdominal lymph nodes and may disseminate to the bone marrow and other organs. Diagnosis typically occurs in individuals aged 60 to 65 years. Its global incidence has increased, attributed to improvements in diagnostic technologies and reporting systems. However, epidemiological studies on FNHL in Brazil, particularly in the Northern region, remain scarce and insufficient to accurately define its local epidemiological profile. Objectives: To analyze mortality patterns associated with follicular non-Hodgkin lymphoma in the state of Pará, Brazil, from 2019 to 2023. Methods: This is a descriptive, retrospective epidemiological study of mortality from FNHL in Pará between 2019 and 2023. Data were extracted from the Mortality Information System (SIM), available on the TABNET/DATASUS platform, using ICD-10 code C82. Variables analyzed included age group, year of death, sex, race/ethnicity, education level, and municipality of residence. Results: A total of 15 FNHL-related deaths were recorded in Pará during the study period, distributed across 11 municipalities. The capital, Belém, reported the highest number of deaths (33.3%, 5/15). The highest annual number of deaths occurred in 2023 (40%, 6/15), followed by 2019 (26.6%, 4/15); the lowest was in 2021, with only one death reported. Most decedents were male (66.6%, 10/15), and 33.3% (5/15) were female. Regarding race/ethnicity, 46.6% (7/15) were brown, 33.3% (5/15) white, and 20% (3/15) black. In terms of education, 13.3% (2/15) had more than 12 years of schooling, while 33.3% (5/15) had no formal education. The highest mortality was observed in individuals aged 80 years and older (33.3%, 5/15), followed by those aged 60–69 years (26.6%, 4/15), and 70–79 years (20%, 3/15). Isolated deaths (6.6%, 1/15 each) occurred in the age groups 5–9, 40–49, and 50–59 years. No deaths were reported in other age groups during the study period. Conclusion: This study underscores the association between FNHL mortality, aging, and social determinants such as education, gender, and race. Individuals with lower educational attainment face barriers to accessing health information, timely diagnosis, and treatment, which increases their mortality risk. The predominance of male deaths may reflect lower healthcare-seeking behavior and delayed treatment initiation. Moreover, structural inequalities continue to hinder healthcare access, contributing to higher mortality among racialized populations. These findings highlight the need for further research and the development of public health strategies tailored to regional and social contexts.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
